Lystig, Ted
Mayo Clinic
tEidos Therapeutics, affiliate of BridgeBio Pharma, San Francisco, California, US
Citations 1
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy
Gillmore, Julian D., Fontana, Marianna, Gibbs, Simon , Grogan, Martha, Hanna, Mazen, Masri, Ahmad , Nativi-Nicolau, José , Rockhold, Frank W. , Shah, Keyur B. , Soman, Prem, Garg, Jyotsna , Xu, Haolin , Cao, Xiaofan, Lystig, Ted, Sinha, Uma, Fox, Jonathan C., Investigators, for the ATTRibute-CM, Gillmore, Julian D , Rockhold, Frank W , Gillmore, Julian D. , Judge, Daniel P. , Cappelli, Francesco, Fontana, Marianna , Garcia-Pavia, Pablo , Grogan, Martha , Hanna, Mazen, Hoffman, James, Maurer, Matthew J. , Obici, Laura , Poulsen, Steen Hvitfeldt , Soman, Prem , Chiswell, Karen , Lystig, Ted, Investigators, for the ATTRibute-CM
Future Cardiology | December 12, 2025 | Volume: 21 | Issue: 12 | Pages: 1017-1025
